Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer

A systematic review

Austin Nguyen, Sheila Bhavsar, Erinn Riley, Gabriel Caponetti, Devendra K. Agrawal

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.

Original languageEnglish (US)
Pages (from-to)382-389
Number of pages8
JournalInternational Archives of Otorhinolaryngology
Volume20
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Head and Neck Neoplasms
PubMed
Neoplasms
Advanced Glycosylation End Product-Specific Receptor
Inflammation
Genes
Carcinoma, squamous cell of head and neck
Proteins

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer : A systematic review. / Nguyen, Austin; Bhavsar, Sheila; Riley, Erinn; Caponetti, Gabriel; Agrawal, Devendra K.

In: International Archives of Otorhinolaryngology, Vol. 20, No. 4, 01.10.2016, p. 382-389.

Research output: Contribution to journalReview article

@article{708f2009a85c4e1d9aabe08af2d6048e,
title = "Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer: A systematic review",
abstract = "Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.",
author = "Austin Nguyen and Sheila Bhavsar and Erinn Riley and Gabriel Caponetti and Agrawal, {Devendra K.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1055/s-0036-1583168",
language = "English (US)",
volume = "20",
pages = "382--389",
journal = "International Archives of Otorhinolaryngology",
issn = "1809-9777",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck cancer

T2 - A systematic review

AU - Nguyen, Austin

AU - Bhavsar, Sheila

AU - Riley, Erinn

AU - Caponetti, Gabriel

AU - Agrawal, Devendra K.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.

AB - Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced glycation end-products. Expression of high mobility group box 1 and the receptor for advanced glycation end-products has been described in many cancers. Objectives To systematically review the available literature using PubMed and Web of Science to evaluate the clinical value of high mobility group box 1 and the receptor for advanced glycation end-products in head and neck squamous cell carcinomas. Data synthesis A total of eleven studies were included in this review. High mobility group box 1 overexpression is associated with poor prognosis and many clinical and pathological characteristics of head and neck squamous cell carcinomas patients. Additionally, the receptor for advanced glycation end-products demonstrates potential value as a clinical indicator of tumor angiogenesis and advanced staging. In diagnosis, high mobility group box 1 demonstrates low sensitivity. Conclusion High mobility group box 1 and the receptor for advanced glycation end-products are associated with clinical and pathological characteristics of head and neck squamous cell carcinomas. Further investigation of the prognostic and diagnostic value of these molecules is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84992133878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992133878&partnerID=8YFLogxK

U2 - 10.1055/s-0036-1583168

DO - 10.1055/s-0036-1583168

M3 - Review article

VL - 20

SP - 382

EP - 389

JO - International Archives of Otorhinolaryngology

JF - International Archives of Otorhinolaryngology

SN - 1809-9777

IS - 4

ER -